E7090 + exemestane

E7090 + exemestane is an investigational combination therapy comprising E7090 (tasurgratinib), a selective small molecule inhibitor of fibroblast growth factor receptor 1–3 (FGFR1–3), and exemestane, a steroidal aromatase inhibitor. E7090 targets FGFR-dependent tumor growth and signaling, while exemestane irreversibly inhibits aromatase, blocking estrogen synthesis and thereby suppressing estrogen receptor-mediated tumor proliferation. The combination is being developed for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2−), recurrent or metastatic breast cancer, particularly in patients who have received prior CDK4/6 inhibitor therapy[1][2][5]. Preclinical and clinical studies have shown this combination has manageable safety and tolerability, with preliminary evidence of antitumor activity in FGFR-driven and HR+/HER2− advanced breast cancer after CDK4/6 inhibitor exposure[2]. The developers and trial sponsor is Eisai.

Brand names

Aromasin

Other names

tasurgratinibexemestane